Additionally, AK129, a bispecific antibody targeting both PD‐1 and LAG‐3, is currently being evaluated in a clinical study to assess its efficacy and safety in patients with unresectable locally advanced or metastatic GC/GEJC (NCT06586294). This evidence concerns the gene PDCD1 and gastric cancer.